alveolar bone defects
Conditions
Interventions
Experimental group:Use absorbable collagen membranes
Control group:Using oral absorbable biofilms
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years, gender is not limited; 2. A single tooth (at least one adjacent tooth) needs to be extracted; 3. No bone wall defect or unilateral bone wall defect after tooth extraction; 4. Those who volunteered to participate in this clinical trial and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Those who can cause artifacts in oral imaging detection (such as metal dentures, porcelain teeth, etc.); 2. Patients with alveolar bone defects caused by aggressive and malignant bone tumors; 3. Buccal bone plate fenestration; 4. The height of the buccal bone defect exceeds 2/3 of the root length; 5. Patients with alveolar process fracture after tooth extraction; 6. Those with local inflammation, including untreated periodontal disease; 7. There is untreated acute apical periodontitis in the test teeth and adjacent teeth; 8. Poorly controlled diabetic patients (fasting blood glucose is still >=8.0 mmol/L after drug control); 9. Patients with insufficiency or abnormal liver and kidney function (ALT, AST > 1.5 times the upper limit of normal value, creatinine exceeds the upper limit of normal value and the investigator judges it to be clinically significant); 10. Patients with a history of local radiotherapy on the head or neck in the past 3 months; 11. Those with bleeding tendency or coagulation disorders; 12. Those who have received or are receiving drug therapy that may affect or promote bone metabolism in the past 3 months, including calcitonin, parathyroid hormone, bisphosphonates, steroid hormones, immunosuppressants and other drugs that researchers believe may affect bone metabolism; 13. Drug, alcohol, drug abuse or self-reported smoking/tobacco equivalents/chewing tobacco >10 cigarettes per day; 14. Physical or mental impairments affecting oral hygiene care; 15. Those who are known to be allergic to bovine sources or xenogeneic proteins; 16. Those with uncontrolled systemic diseases who cannot perform bone graft surgery; 17. Pregnant/lactating patients or patients who have a pregnancy plan within six months; 18. Patients who have participated in or are participating in clinical trials of other drugs/devices within 3 months; 19. The investigator believes that other patients are not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the height change value of alveolar ridge; | — |
Countries
China
Contacts
Public ContactWang Xiao
Outcome results
None listed